Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tyra Biosciences, Inc. TYRA
$12.60
+$0.33 (2.61%)
На 18:04, 12 мая 2023
+34.92%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
576980790.00000000
-
week52high
16.86
-
week52low
4.93
-
Revenue
0
-
P/E TTM
-24
-
Beta
0.00000000
-
EPS
-1.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мар 2023 г. в 20:05
Описание компании
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 23 июн 2022 г. | |
| Jefferies | Buy | Hold | 08 мар 2022 г. |
| Jefferies | Hold | Buy | 08 ноя 2021 г. |
| Jefferies | Buy | 11 окт 2021 г. | |
| Cowen & Co. | Outperform | 11 окт 2021 г. | |
| Oppenheimer | Outperform | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fuhrman Alan | A | 328000 | 328000 | 01 янв 2023 г. |
| Fuhrman Alan | A | 32800 | 32800 | 01 янв 2023 г. |
| Patel Piyush R. | D | 82236 | 56276 | 12 окт 2022 г. |
| Tada Hiroomi | A | 81237 | 612 | 15 сент 2022 г. |
| van den Boom Esther | A | 121897 | 1452 | 15 сент 2022 г. |
| Hudkins Robert L. | A | 273576 | 1040 | 15 сент 2022 г. |
| Patel Piyush R. | A | 138512 | 1040 | 15 сент 2022 г. |
| van den Boom Esther | A | 89054 | 89054 | 06 сент 2022 г. |
| van den Boom Esther | A | 105000 | 105000 | 06 сент 2022 г. |
| Patel Piyush R. | A | 30924 | 30924 | 06 сент 2022 г. |
Новостная лента
Tyra Biosciences to Present at Upcoming Investor Conferences
PRNewsWire
10 ноя 2022 г. в 16:20
CARLSBAD, Calif. , Nov. 10, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November: H.C.
Tyra Biosciences to Participate at September 2022 Investor Conferences
PRNewsWire
08 сент 2022 г. в 16:05
CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences: H.C.
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
PRNewsWire
05 сент 2022 г. в 08:15
CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting preclinical data on TYRA-300 during a poster session at the European Society for Medical Oncology (ESMO) 2022 Congress, being held in person September 9-13, 2022 in Paris, France.